Appointed as the chief physician of Sun Yat-sen University Cancer Prevention and Treatment Center, and served as the deputy director of the Department of Clinical Research, the head of the Stage I ward, the attending professor, and the supervisor of doctoral students since 2017.

Since the establishment of Phase I Ward of Cancer Prevention and Treatment Center in 2014, responsible for the daily medical management of Phase I Ward of New Anti-tumor Drugs and Clinical Research Day Ward in Yuexiu Hospital. During the 14th Five-Year Plan period, the percentage of First in Class new drug projects in our Phase I ward ranked the first in Chinese oncology hospitals, and our Phase I ward has developed into the most influential Phase I clinical research ward for new antitumor drugs in China.

Academically, made certain scientific achievements in clinical, translational and basic research on immuno/targeted/chemotherapeutic drugs for lung/nasopharyngeal cancer, and published 158 papers in international journals, of which 67 papers were published as first (including co-first) or corresponding (including co-corresponding) authors in the well-known journals, such as Lancet Oncology, Signal Transduction and Targeted Therapy, Cancer Cell, J Hematology & Oncology, J Thoracic Oncology, J Immunotherapy of Cancer, Cancer Letters and so on. Responsible for more than 50 international and domestic phase I clinical studies, and led a phase III clinical study of a multicenter randomized controlled dual-targeted combination therapy for lung cancer. Currently, as the first person in charge, presided three top-level projects of National Natural Science Foundation of China (NSFC), two projects of Guangdong Provincial Natural Science Foundation (GDNSF), one project of Guangzhou Key Research and Development Program (GZKRP), one project of Sun Yat-sen University (SYSU) Clinical Medical Research Program (CMRP), and one project of Heathcote-Junshi Tumor Immunology Research Fund (JRF). Many research results have been presented at the American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO-Asia), such as poster discussions and oral presentations.

In order to strengthen the multidisciplinary cooperation, formed the Specialized Committee on Precision Therapy and Clinical Research of Lung Cancer of Guangdong Clinical Medical Association and acted as the chairman of the committee. Trained 4 master's students and 4 doctoral students, 2 of whom have published high-level papers (IF>10) as the first author; supervised 6 residents, 2 of whom have been awarded the National Natural Youth Foundation of China and 3 of whom have been awarded the post-doctoral program; supervised dozens of trainees, and trained talents for the establishment of the GCP organization in the sister hospitals; actively involved in the lectures for the large classes of undergraduates, and responsible for the clinical teaching of the department and the teaching work.

Precision treatment of advanced lung cancer, nasopharyngeal cancer

Clinical research of new anti-tumor drugs 

1993-1998, Kunming Medical College Clinical Medicine Major, Bachelor Degree;

2000-2003, First Affiliated Hospital of Sun Yat-Sen university, Master Degree;

2007-2011, Sun Yat-Sen University Cancer Center, PhD.

2016-2017, University of Texas MD Anderson Cancer Center, visiting scholar